Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Advancements analyze identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CX